title: Quinpirole attenuates the striatal immediate early gene expression, but not the hyperactivity, induced by the serotonin agonist RU-24969.
abstract: Systemic administration of the mixed 5-HT(1A/1B) agonist RU-24969 has been shown to produce a dramatic increase in locomotor activity and to induce robust c-Fos expression in the rat striatum. Previous studies have also shown that pretreatment with the D2-like dopamine agonist quinpirole virtually abolishes RU-24969-induced striatal c-Fos expression. The present study was undertaken to determine whether the effects of RU-24969 on immediate early gene expression extend to the additional Fos family transcription factors FosB and Fra-2. Additionally, this study quantitatively examined the effect of quinpirole pretreatment on the ability of RU-24969 to induce both locomotor hyperactivity and striatal immediate early gene expression. RU-24969 alone produced elevations in locomotor activity and induced clear expression of c-Fos, FosB and Fra-2 throughout the entire striatal complex. Quinpirole pretreatment virtually abolished RU-24969-induced expression of all three transcription factors, but did not alter the elevated locomotor activity produced by RU-24969. These results demonstrate that the effects of RU-24969 on locomotor activity can be dissociated from its effects on immediate early gene expression within the striatum.
authors.affiliation: The University of Illinois at Chicago, Department of Psychology, 60607-7137, USA.
authors.forename: D F
authors.initials: DF
authors.lastname: Cook
authors.forename: D
authors.initials: D
authors.lastname: Wirtshafter
mesh_terms: D017109:Akathisia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D003342:Corpus Striatum / Q000502:physiology*; D004268:DNA-Binding Proteins / Q000235:genetics; D004298:Dopamine / Q000235:genetics; D018491:Dopamine Agonists / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D051921:Fos-Related Antigen-2; D015870:Gene Expression / Q000187:drug effects; D017781:Genes, Immediate-Early / Q000502:physiology*; D007211:Indoles / Q000494:pharmacology*; D008124:Locomotion / Q000187:drug effects; D008297:Male; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics; D019257:Quinpirole / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044302:Receptor, Serotonin, 5-HT1B; D011985:Receptors, Serotonin / Q000235:genetics; D012701:Serotonin / Q000235:genetics; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D014157:Transcription Factors / Q000235:genetics
chemical_list: D004268:DNA-Binding Proteins; D018491:Dopamine Agonists; D051921:Fos-Related Antigen-2; C497874:Fosl2 protein, rat; D007211:Indoles; D016760:Proto-Oncogene Proteins c-fos; D044302:Receptor, Serotonin, 5-HT1B; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D014157:Transcription Factors; D019257:Quinpirole; C025145:5-methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1H indole; D012701:Serotonin; D004298:Dopamine